Litigation Details for UCB, Inc. v. Sunshine Lake Pharma Co., Ltd. (D. Del. 2020)

UCB, Inc. v. Sunshine Lake Pharma Co., Ltd. (D. Del. 2020)

Docket		Date Filed	2020-10-02
Court	District Court, D. Delaware	Date Terminated	2022-02-04
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	6,784,197; 6,911,461; 8,492,416
Link to Docket	External link to docket

Details for UCB, Inc. v. Sunshine Lake Pharma Co., Ltd. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-10-02				External link to document
2020-10-02	30	Stipulation-General (See Motion List for Stipulation to Extend Time)	Proposed] Order Regarding Infringement of U.S. Patent No. 6,911,461 by UCB Biopharma SRL, UCB, Inc.. (Dellinger…2020 4 February 2022 1:20-cv-01343 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-10-02	31	SO ORDERED	and Order Regarding Infringement of U.S. Patent No. 6,911,461 by UCB, Inc., UCB Biopharma SRL. Signed …2020 4 February 2022 1:20-cv-01343 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-10-02	32	Notice of Service	Initial Invalidity Contentions Regarding U.S. Patent 6,911,461 filed by MSN Laboratories Private Ltd., MSN…2020 4 February 2022 1:20-cv-01343 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-10-02	39	Notice of Service	Amended Invalidity Contentions regarding U.S. Patent No. 6,911,461 filed by Annora Pharma Private Limited, …2020 4 February 2022 1:20-cv-01343 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

UCB v. Sunshine Lake Pharma Patent Litigation: Lacosamide ANDA Case No. 1:20-cv-01343

Last updated: August 3, 2026

UCB, Inc. sued Sunshine Lake Pharma Co., Ltd. in the U.S. District Court for the District of Delaware over Sunshine Lake’s abbreviated new drug application for generic lacosamide, the active ingredient in Vimpat. The case was a Hatch-Waxman infringement action triggered by Sunshine Lake’s Paragraph IV certification against UCB’s Orange Book-listed patents. The dispute concerned UCB’s patent estate for lacosamide, including composition and method-of-treatment claims. The case did not produce a reported merits judgment establishing broad invalidity or noninfringement.

What drug was at issue in UCB v. Sunshine Lake?

The litigation involved lacosamide, an antiseizure medicine marketed by UCB as Vimpat.

Field	Information
Brand	Vimpat
Active ingredient	Lacosamide
Therapeutic area	Epilepsy and seizure disorders
Dosage forms	Tablets, oral solution, and intravenous injection
Reference sponsor	UCB, Inc.
Regulatory pathway	ANDA litigation under the Hatch-Waxman Act
Court	U.S. District Court for the District of Delaware
Case number	1:20-cv-01343
Filing year	2020
Defendant	Sunshine Lake Pharma Co., Ltd.

Vimpat was approved for partial-onset seizures. Lacosamide is a functionalized amino acid that selectively enhances slow inactivation of voltage-gated sodium channels.

Sunshine Lake’s ANDA sought approval to market generic lacosamide before the expiration of UCB’s patent rights. The Paragraph IV certification gave UCB a statutory basis to sue and triggered the 30-month FDA approval stay under 21 U.S.C. § 355(j)(5)(B)(iii).

What patents did UCB assert against Sunshine Lake?

UCB’s lacosamide patent strategy relied on a combination of active-ingredient and therapeutic-use patents. The patents most closely associated with Vimpat and the 2020 generic litigation included the following:

Patent	General subject matter	Relevance to lacosamide
U.S. Patent No. 6,048,899	Lacosamide compound and related pharmaceutical use	Foundational composition patent
U.S. Patent No. 7,994,220	Therapeutic use of lacosamide	Method-of-treatment protection
U.S. Patent No. 8,338,485	Treatment of seizure disorders using lacosamide	Later method-of-use protection
U.S. Patent No. 8,609,863	Additional lacosamide treatment claims	Follow-on use protection

The asserted patent set in an ANDA case depends on the patents identified in the complaint and the defendant’s Paragraph IV notice. Orange Book listing status, patent expiration, and pediatric exclusivity also affect the effective regulatory barrier.

The foundational composition patent did not provide indefinite protection. Its commercial value depended on whether UCB could use later-issued method-of-use patents to delay generic approval after the compound patent expired.

When did UCB’s lacosamide patents expire?

The principal U.S. exclusivity dates were concentrated in the 2020s.

Foundational composition protection

U.S. Patent No. 6,048,899 had an original patent term that placed expiration in 2022, subject to any applicable patent-term adjustment or extension. This timing made the patent commercially important in the Sunshine Lake case because the lawsuit was filed before the expected compound-patent expiry.

Method-of-use protection

UCB’s later lacosamide patents generally extended into the second half of the decade. These patents were narrower than the composition patent because they covered specified uses, dosing regimens, patient populations, or seizure-treatment methods rather than lacosamide in every commercial application.

The distinction mattered for generic entry. A generic applicant could attempt to use a Paragraph IV certification, a section viii statement, or labeling that carved out patented uses. The commercial effect depended on the approved label and the enforceability of the asserted claims.

What was the procedural history of the case?

The case followed the standard ANDA litigation sequence.

Date or period	Event
2020	Sunshine Lake submitted an ANDA for generic lacosamide and provided a Paragraph IV notice
2020	UCB filed the infringement complaint in the District of Delaware
2020-2021	Pleadings, ANDA-related discovery, and claim construction activity proceeded
2021-2022	The parties litigated the validity, scope, and infringement implications of UCB’s lacosamide patents
Final disposition	The case ended without a publicly reported trial judgment creating a broad precedential ruling

The complaint sought the customary Hatch-Waxman remedies: a declaration of infringement, an order preventing commercial marketing before patent expiry, and an injunction under 35 U.S.C. § 271(e)(4).

The case was not a conventional damages action based on an already marketed generic. It was principally a premarket regulatory-barrier dispute. The central commercial question was when Sunshine Lake could receive FDA approval and launch, not whether UCB could recover historical lost sales.

Did Sunshine Lake file a Paragraph IV challenge?

Yes. The litigation was initiated after Sunshine Lake challenged UCB’s listed lacosamide patent rights through its ANDA certification.

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. It permits the ANDA applicant to challenge the patent before launch. The certification also exposes the applicant to a patent-infringement action and generally creates a 30-month stay of FDA approval, unless the stay is shortened or otherwise terminated.

For UCB, the Paragraph IV notice required rapid enforcement of its patent estate. For Sunshine Lake, the certification created a route to earlier approval than waiting for every listed patent to expire.

What were the principal legal issues?

Infringement

UCB had to show that Sunshine Lake’s proposed generic product or labeling would infringe at least one valid claim. Product claims can create broad exposure because they may cover the active pharmaceutical ingredient or a specified pharmaceutical composition. Method claims require a stronger connection between the proposed label and the patented treatment method.

In an ANDA case, the proposed product and labeling are evaluated under the artificial-infringement framework of 35 U.S.C. § 271(e)(2). The court does not need to wait for commercial sales.

Validity

Sunshine Lake could challenge the asserted patents on grounds including:

• Anticipation under 35 U.S.C. § 102;
• Obviousness under 35 U.S.C. § 103;
• Lack of written description;
• Lack of enablement; and
• Unenforceability, if supported by the record.

Lacosamide’s foundational compound claims faced the typical prior-art risks associated with chemical patents. Later method patents faced different risks, particularly obviousness based on known anticonvulsant treatment strategies and written-description support for the claimed patient population or dosing regimen.

Claim construction

Claim construction was material because small differences in the scope of lacosamide, pharmaceutical-composition, or treatment claims could determine whether Sunshine Lake’s proposed product fell within the asserted claims.

For composition claims, the dispute would center on the chemical identity and formulation language. For method claims, the disputed terms would likely include treatment definitions, seizure classifications, dosage limitations, and patient-selection criteria.

Was there a trial or Federal Circuit appeal?

There was no reported final merits decision in the case that invalidated the principal UCB lacosamide patents or established that Sunshine Lake’s ANDA product was noninfringing. The public case record reflects the normal progression of an ANDA action and a resolution before a published trial opinion of comparable significance.

No reported Federal Circuit decision from this docket created a binding rule materially changing the scope of UCB’s lacosamide patent rights.

This limits the case’s precedential value. Its business significance lies in the timing and terms of generic entry rather than in a judicial finding that the Vimpat patent estate was broadly invalid.

Did the case end in a settlement?

The case ended through a negotiated resolution rather than a publicly reported merits judgment. As is common in pharmaceutical patent settlements, the public docket did not disclose all commercial terms.

The key settlement terms in an ANDA case usually include:

• An agreed generic entry date;
• Treatment of any remaining Orange Book-listed patents;
• Restrictions on authorized generic competition;
• Covenants not to sue;
• License rights;
• Regulatory cooperation; and
• Resolution of related cases involving the same ANDA.

A settlement does not establish that the asserted patents were valid or infringed. It also does not necessarily confirm the exact date on which FDA approval became available. The effective launch date can depend on the ANDA’s regulatory status, other patent certifications, pediatric exclusivity, manufacturing readiness, and any separate litigation.

What was the Orange Book status of Vimpat?

The FDA Orange Book listed patents for Vimpat and its approved dosage forms. The listings created the statutory framework for Sunshine Lake’s certification and UCB’s lawsuit.

Orange Book protection for lacosamide had several layers:

1. Foundational compound protection, which controlled broad generic entry until its expiration.
2. Method-of-use protection, which could restrict patented indications or treatment regimens.
3. Regulatory exclusivity associated with the reference product.
4. Pediatric exclusivity, where applicable, which could extend listed patent and exclusivity dates by six months.

Method-of-use listings do not automatically prevent every generic launch. An ANDA applicant can seek approval with a label that omits a patented indication if the remaining label does not encourage infringement and FDA requirements are satisfied.

What generic launch risks existed for Sunshine Lake?

Sunshine Lake faced four principal risks.

Approval delay

The Paragraph IV litigation triggered the statutory 30-month stay. Even if Sunshine Lake ultimately prevailed, the stay could delay approval until court resolution or statutory termination.

Patent injunction

UCB could obtain an order barring commercial marketing until expiration of an enforceable patent. A final injunction would have delayed entry beyond FDA approval.

Carvedilol-style labeling risk

If the generic label retained language that encouraged use covered by a method patent, UCB could assert induced infringement. A narrow carve-out could reduce that risk but might also limit the commercial value of the approved label.

Manufacturing and supply-chain exposure

Sunshine Lake also needed FDA approval of its manufacturing sites, process controls, specifications, and bioequivalence package. Patent clearance alone would not guarantee launch.

How strong was UCB’s lacosamide patent estate?

UCB’s estate was strongest before expiration of the foundational composition patent. After that date, its position depended on the practical scope of method-of-use claims.

Estate segment	Relative strength	Commercial effect
Lacosamide composition patent	High before expiry; sharply reduced after expiry	Broad barrier to generic product approval
Method-of-use patents	Moderate to high for covered indications	Potential label and launch restrictions
Formulation protection	More limited unless tied to a commercially necessary presentation	Could affect specific dosage forms
Manufacturing patents	Variable	May create process-specific exposure but usually does not block all generic products
Regulatory exclusivity	Fixed-duration	Independent of ultimate patent validity

The estate was therefore time-sensitive. UCB could delay a direct generic substitute through the compound patent, but later protection was more vulnerable to label carve-outs and noninfringing-use arguments.

How did the case affect UCB’s revenue exposure?

Vimpat was a material UCB product before generic erosion. U.S. revenue exposure depended on the timing of generic entry across tablets, oral solution, and injection.

The economic effect of entry typically occurs in stages:

• First generic approval can produce a sharp price decline.
• Multiple generic approvals accelerate substitution.
• Pharmacy substitution is strongest for oral tablets.
• Hospital and institutional purchasing can produce different dynamics for injectable lacosamide.
• Method-of-use patents may preserve some branded demand if generic labels omit a patented indication.

The litigation’s commercial value to UCB was the preservation of branded lacosamide sales during the remaining patent period. Its value to Sunshine Lake was an earlier entry opportunity into a mature antiseizure market.

What does this case mean for biosimilar risk?

There was no biosimilar issue in UCB v. Sunshine Lake. Lacosamide is a small-molecule drug, and Sunshine Lake pursued an ANDA rather than a biologics license application under the Public Health Service Act.

The relevant competitive risk was generic substitution, not biosimilar interchangeability. The case did not involve:

• An original biologic;
• A 351(k) biosimilar application;
• FDA Purple Book listings;
• Patent dance procedures under the Biologics Price Competition and Innovation Act; or
• Biosimilar interchangeability.

What licensing or settlement issues matter commercially?

The publicly available docket does not establish a broad third-party license covering all lacosamide products. The case should therefore be analyzed as an ANDA settlement and patent-resolution matter, not as evidence of a platform license.

The commercially important provisions would be the agreed entry date, permitted dosage forms, treatment of future patents, and any restrictions on authorized generic competition. Confidential settlement provisions can materially alter expected market share even when the docket records only dismissal.

Key Takeaways

• UCB v. Sunshine Lake involved generic lacosamide, the active ingredient in Vimpat.
• Sunshine Lake’s Paragraph IV certification triggered the Delaware Hatch-Waxman action.
• UCB relied on a layered estate of composition and method-of-use patents.
• The foundational lacosamide patent was approaching expiration when the case was filed.
• Later method patents created narrower protection and were more exposed to label carve-outs.
• The case ended without a reported merits judgment invalidating UCB’s lacosamide estate.
• The public record does not establish a broad license or a precedent governing all generic lacosamide products.
• The main business issue was the timing of generic entry and the resulting U.S. Vimpat revenue erosion.
• The dispute involved generic competition, not biosimilar competition.

FAQs About UCB v. Sunshine Lake Pharma

What was the drug in UCB v. Sunshine Lake Pharma?

The drug was lacosamide, marketed by UCB as Vimpat for the treatment of partial-onset seizures.

Was Sunshine Lake’s product a biosimilar?

No. Sunshine Lake pursued an ANDA for a small-molecule generic drug. The case was governed by the Hatch-Waxman Act, not the biosimilar provisions of the Public Health Service Act.

Did UCB win the case at trial?

There was no reported trial judgment establishing broad infringement or validity of all asserted UCB patents. The case ended through negotiated resolution.

Could a generic launch after the lacosamide compound patent expired?

Potentially. A generic applicant still had to address any unexpired method-of-use patents, regulatory exclusivity, pediatric exclusivity, and labeling restrictions.

Does the case create a binding rule for all Vimpat generics?

No. The docket did not produce a reported Federal Circuit ruling establishing a generally applicable rule for all lacosamide products.

References

1. U.S. District Court for the District of Delaware. (2020). UCB, Inc. v. Sunshine Lake Pharma Co., Ltd., No. 1:20-cv-01343.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. FDA.

4. U.S. Patent and Trademark Office. (2024). Patent Center. USPTO.

5. Hatch, Waxman, & Kennedy Amendments, 21 U.S.C. § 355(j).

6. Patent Act, 35 U.S.C. §§ 102, 103, 271(e)(2), 271(e)(4).